Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients

  • Jepsen P
  • Watson H
  • Andersen P
 et al. 
  • 3


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Background & Aims It remains unclear whether diabetes increases the risk for hepatic encephalopathy (HE) in cirrhotic patients. We examined this question using data from three randomized trials of satavaptan, a vasopressin receptor antagonist that does not affect HE risk, in cirrhotic patients with ascites. Methods The trials included 1198 patients, and we excluded those with HE before or at randomization and followed the remaining patients for the one year duration of the trials. They were examined for HE regularly, and we compared rates of first-time overt HE between diabetics and non-diabetic patients using Cox regression, adjusting for gender, age, ascites severity, cirrhosis etiology, Child-Pugh class, creatinine, bilirubin, INR, sodium, potassium, albumin, platelets, lactulose use, benzodiazepine/barbiturate use, spironolactone dose, furosemide dose, potassium-sparing diuretic dose, and CirCom comorbidity score. Results We included 862 patients of whom 193 (22%) had diabetes. In total, they experienced 115 first-time episodes of overt HE during the follow-up. Fewer diabetics than non-diabetic patients were in Child-Pugh class C at baseline (13% vs. 23%), yet they had higher cumulative risk of first-time overt HE (26.0% vs. 15.8% after 1 year), and their episodes of first-time overt HE were more likely to progress beyond grade 2 (64% vs. 42% of episodes progressed to grade 3 or 4, p = 0.01 for independence between diabetes and highest HE grade). After the confounder adjustment, the hazard ratio of first-time overt HE for diabetics vs. non-diabetic patients was 1.86 (95% CI 1.20-2.87). Conclusions Diabetes increased the risk of first-time overt HE among cirrhotic patients with ascites. Copyright © 2015 European Association for the Study of the Liver.

Author-supplied keywords

  • Child Pugh score
  • Cirrhosis
  • Diabetes mellitus
  • End-stage liver disease
  • Hepatic encephalopathy
  • Prognosis
  • adult
  • aged
  • albumin
  • albumin/ec [Endogenous Compound]
  • antidiabetic agent
  • article
  • ascites
  • ascites/dt [Drug Therapy]
  • barbituric acid derivative
  • benzodiazepine
  • bilirubin
  • bilirubin/ec [Endogenous Compound]
  • comorbidity
  • constipation
  • controlled study
  • creatinine
  • creatinine/ec [Endogenous Compound]
  • diabetes mellitus/dt [Drug Therapy]
  • diabetic patient
  • disease course
  • drug safety
  • drug use
  • electrolyte disturbance
  • end stage liver disease
  • etiology
  • female
  • follow up
  • furosemide
  • gastrointestinal hemorrhage
  • gender
  • glucose blood level
  • glucose/ec [Endogenous Compound]
  • hazard ratio
  • hepatitis B
  • hepatitis C
  • human
  • hyperglycemia
  • independence
  • insulin treatment
  • insulin/dt [Drug Therapy]
  • international normalized ratio
  • lactulose
  • liver cirrhosis
  • major clinical study
  • male
  • metformin/dt [Drug Therapy]
  • middle aged
  • oral antidiabetic agent/dt [Drug Therapy]
  • patient
  • potassium
  • potassium sparing diuretic agent
  • potassium/ec [Endogenous Compound]
  • priority journal
  • proportional hazards model
  • randomization
  • randomized controlled trial(topic)
  • risk
  • risk factor
  • satavaptan
  • satavaptan/ct [Clinical Trial]
  • satavaptan/dt [Drug Therapy]
  • sodium
  • sodium/ec [Endogenous Compound]
  • spironolactone
  • thrombocyte
  • treatment duration
  • vasopressin receptor antagonist

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in


  • P Jepsen

  • H Watson

  • P K Andersen

  • H Vilstrup

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free